Option Care Health (NASDAQ:OPCH) Upgraded to “Strong-Buy” at Stephens

Stephens upgraded shares of Option Care Health (NASDAQ:OPCH) to a strong-buy rating in a report published on Thursday morning,Zacks.com reports.

OPCH has been the topic of several other reports. Citigroup reissued an “outperform” rating on shares of Option Care Health in a research report on Friday, October 31st. Barrington Research reaffirmed an “outperform” rating and issued a $38.00 price target on shares of Option Care Health in a report on Friday, October 31st. Wall Street Zen raised Option Care Health from a “hold” rating to a “buy” rating in a report on Saturday, December 6th. Deutsche Bank Aktiengesellschaft raised their target price on Option Care Health from $31.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Bank of America upped their price target on shares of Option Care Health from $32.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, Option Care Health presently has an average rating of “Moderate Buy” and an average price target of $36.27.

Option Care Health Stock Up 1.0%

Shares of OPCH traded up $0.34 during midday trading on Thursday, reaching $33.24. 1,867,592 shares of the company were exchanged, compared to its average volume of 1,839,138. The company has a current ratio of 1.56, a quick ratio of 1.05 and a debt-to-equity ratio of 0.85. Option Care Health has a 1-year low of $22.29 and a 1-year high of $35.53. The company has a market cap of $5.28 billion, a price-to-earnings ratio of 26.38, a P/E/G ratio of 2.22 and a beta of 0.80. The stock has a 50-day moving average price of $28.74 and a 200-day moving average price of $29.36.

Insider Activity

In other news, Director Harry M. Jansen Kraemer, Jr. bought 38,000 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The stock was acquired at an average price of $25.98 per share, with a total value of $987,240.00. Following the completion of the purchase, the director directly owned 413,390 shares of the company’s stock, valued at $10,739,872.20. This represents a 10.12% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.64% of the company’s stock.

Institutional Investors Weigh In On Option Care Health

A number of large investors have recently made changes to their positions in the company. Strs Ohio purchased a new stake in Option Care Health in the 1st quarter worth approximately $636,000. Prospector Partners LLC grew its holdings in Option Care Health by 22.9% during the first quarter. Prospector Partners LLC now owns 111,200 shares of the company’s stock valued at $3,886,000 after purchasing an additional 20,700 shares during the last quarter. Andina Capital Management LLC bought a new stake in shares of Option Care Health during the 1st quarter worth $513,000. Advantage Alpha Capital Partners LP grew its stake in Option Care Health by 78.7% in the 1st quarter. Advantage Alpha Capital Partners LP now owns 214,619 shares of the company’s stock valued at $7,501,000 after buying an additional 94,528 shares during the last quarter. Finally, Boston Partners raised its holdings in Option Care Health by 34.8% in the 2nd quarter. Boston Partners now owns 952,299 shares of the company’s stock worth $30,311,000 after acquiring an additional 245,990 shares during the period. Institutional investors and hedge funds own 98.05% of the company’s stock.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.